—

Subcutaneous Tepezza’s Phase 3 success and MariTide weight loss data drive specialty and metabolic portfolio execution, lifting Tepezza revenue to $1.9 billion (+3% YoY) and underpinning consensus quarterly revenue of $8.51 billion (+4.4% YoY), while EPS guidance of $4.74 reflects a 3.3% year-over-year decline.

Demand for steep discounts through initiatives like TrumpRx and government-imposed reimbursement policies is intensifying pricing pressure, while escalating biosimilar competition threatens franchise margins. Uncertain regulatory timelines—for example, conditional Chinese nods on a bispecific T-cell engager and undisclosed filings for subcutaneous Tepezza—compound risks. Manufacturing concentrates in a few key sites, leaving supply vulnerable to disease outbreaks, liability claims and third-party limits. Licensing partnerships and emerging subcutaneous delivery models, along with a rising need for specialized pharma-AI skills, are reshaping competitive and regulatory frameworks.

Competition fears from Amgen’s strong Phase 3 results have soured sentiment toward Viridian Therapeutics, while market participants are broadly bullish on Amgen, praising its undervaluation, robust earnings outlook, and top-tier buy ratings.